Effect of prior beta-blocker use on in-hospital atrial fibrillation development in patients with ST-elevation myocardial infarction

References

• Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan G-A, Dilaveris PE, et al. ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the Europea. Eur Heart J. 2021;42:373–498.
   PubMed Web of Science ®Google Scholar
• Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J. 2009;30:1038–45.
   PubMed Web of Science ®Google Scholar
• Lubbe WF, Podzuweit T, Opie LH. Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload: implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors. J Am Coll Cardiol. 1992;19:1622–33. doi:https://doi.org/10.1016/0735-1097(92)90629-2.
   PubMed Web of Science ®Google Scholar
• Roolvink V, Ibáñez B, Ottervanger JP, Pizarro G, van Royen N, Mateos A, Dambrink J-HE, Escalera N, Lipsic E, Albarran A, et al. Early intravenous beta-blockers in patients with ST-segment elevation myocardial infarction before primary percutaneous coronary intervention. J Am Coll Cardiol. 2016;67:2705–15.
   PubMedGoogle Scholar
• Ibanez B, MacAya C, Sánchez-Brunete V, Pizarro G, Fernández-Friera L, Mateos A, Fernández-Ortiz A, García-Ruiz JM, García-Álvarez A, Iñiguez A, et al. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the effect of metoprolol in cardioprotection during an acute myocardial infarction (METOCARD-CNIC) tri. Circulation. 2013;128:1495–503.
   PubMed Web of Science ®Google Scholar
• Hirschl MM, Wollmann CG, Erhart F, Brunner W, Pfeffel F, Gattermeier M, Steger F, Mayr H. Benefit of immediate beta-blocker therapy on mortality in patients with ST-segment elevation myocardial infarction. Crit Care Med. 2013;41:1396–404.
   PubMed Web of Science ®Google Scholar
• Demidenko E. Sample size determination for logistic regression revisited. Stat Med. 2007;26:3385–97. doi:https://doi.org/10.1002/sim.2771.
   PubMed Web of Science ®Google Scholar
• Pesaro AE, Soeiro A de M, Serrano CV, Giraldez RR, Ladeira RT, Nicolau JC. Effect of beta-blockers on the risk of atrial fibrillation in patients with acute myocardial infarction. Clinics (Sao Paulo, Brazil). 2010;65:265–70.
   PubMed Web of Science ®Google Scholar
• Goldberg RJ, Seeley D, Becker RC, Brady P, Chen ZY, Osganian V, Gore JM, Alpert JS, Dalen JE. Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction: a community-wide perspective. Am Heart J. 1990;119:996–1001.
   PubMed Web of Science ®Google Scholar
• Wong CK, White HD, Wilcox RG, Criger DA, Califf RM, Topol EJ, Ohman EM. New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. Am Heart J. 2000;140:878–85.
   PubMed Web of Science ®Google Scholar
• Batra G, Svennblad B, Held C, Jernberg T, Johanson P, Wallentin L, Oldgren J. All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome. Heart (British Cardiac Society). 2016;102:926–33.
   PubMed Web of Science ®Google Scholar
• Pedersen OD, Bagger H, Køber L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 1999;100:376–80.
   PubMed Web of Science ®Google Scholar
• Singh JP, Kulik A, Levin R, Ellinor PT, Ruskin J, Avorn J, Choudhry NK. Renin-angiotensin-system modulators and the incidence of atrial fibrillation following hospitalization for coronary artery disease. Europace. 2012;14:1287–93.
   PubMed Web of Science ®Google Scholar
• Batra G, Lindhagen L, Andell P, Erlinge D, James S, Spaak J, Oldgren J. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are associated with improved outcome but do not prevent new-onset atrial fibrillation after acute myocardial infarction. J Am Heart Assoc. 2017 March 1;6. Epub ahead of print. doi:https://doi.org/10.1161/JAHA.116.005165
   Google Scholar
• Ozaydin M, Turker Y, Erdogan D, Karabacak M, Dogan A, Varol E, Gonul E, Altinbas A. The association between previous statin use and development of atrial fibrillation in patients presenting with acute coronary syndrome. Int J Cardiol. 2010;141(2):147–50. doi:https://doi.org/10.1016/j.ijcard.2008.11.172.
   PubMed Web of Science ®Google Scholar
• Ramani G, Zahid M, Good CB, Macioce A, Sonel AF. Comparison of frequency of new-onset atrial fibrillation or flutter in patients on statins versus not on statins presenting with suspected acute coronary syndrome. Am J Cardiol. 2007;100(3):404–05. doi:https://doi.org/10.1016/j.amjcard.2007.03.034.
   PubMed Web of Science ®Google Scholar
• Pratt C, Lichstein E. Ventricular antiarrhythmic effects of beta-adrenergic blocking drugs: a review of mechanism and clinical studies. J Clin Pharmacol. 1982;22:335–47. doi:https://doi.org/10.1002/j.1552-4604.1982.tb02684.x.
   PubMed Web of Science ®Google Scholar
• Haverkamp W, Gülker H, Hindricks G, Breithardt G. Effects of beta-blockade on the incidence of ventricular tachyarrhythmias during acute myocardial ischemia: experimental findings and clinical implications. Basic Res Cardiol. 1990;85(Suppl 1):293–303. doi:https://doi.org/10.1007/978-3-662-11038-6_24.
   PubMedGoogle Scholar
• Anzai T, Yoshikawa T, Takahashi T, Maekawa, Y, Okabe, T, Asakaura, Y, Satoh, T, Mitamura, H, Ogawa, S. Early use of beta-blockers is associated with attenuation of serum C-reactive protein elevation and favorable short-term prognosis after acute myocardial infarction. Cardiology. 2003;99:47–53.
   PubMed Web of Science ®Google Scholar
• Herlitz J, Waagstein F, Lindqvist J, Swedberg K, Hjalmarson, A. Effect of metoprolol on the prognosis for patients with suspected acute myocardial infarction and indirect signs of congestive heart failure (a subgroup analysis of the Göteborg Metoprolol Trial). Am J Cardiol. 1997 November 13;80:40J–44J. Epub ahead of print. doi:https://doi.org/10.1016/S0002-9149(97)00838-2.
   PubMed Web of Science ®Google Scholar
• Kopecky SL. Effect of beta blockers, particularly carvedilol, on reducing the risk of events after acute myocardial infarction. Am J Cardiol. 2006;98:1115–19. doi:https://doi.org/10.1016/j.amjcard.2006.05.039.
   PubMedGoogle Scholar
• McMurray J, Køber L, Robertson M, Dargie H, Colucci W, Lopez-Sendon J, Remme W, Sharpe DN, Ford I. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the carvedilol post-infarct survival control in left ventricular dysfunction (CAPRICORN) trial. J Am Coll Cardiol. 2005;45:525–30.
   PubMed Web of Science ®Google Scholar
• Califf RM, Lokhnygina Y, Velazquez EJ, McMurray, JJV, Leimberger JD, Lewis EF, Diaz R, Murin J, Pfeffer MA. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial). Am J Cardiol. 2009;104:151–57.
   PubMedGoogle Scholar
• Pesaro AE, de M SA, Serrano CV, Giraldez RR, Ladeira RT, Nicolau JC. Effect of β-blockers on the risk of atrial fibrillation in patients with acute myocardial infarction. Clinics. 2010;65:265.
   PubMed Web of Science ®Google Scholar
• Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, Xie JX, Liu LS. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet (London, England). 2005;366:1622–32.
   PubMed Web of Science ®Google Scholar
• Ozasa N, Kimura T, Morimoto T, Hou H, Tamura T, Shizuta S, Nakagawa Y, Furukawa Y, Hayashi Y, Nakao K, et al. Lack of effect of oral beta-blocker therapy at discharge on long-term clinical outcomes of ST-segment elevation acute myocardial infarction after primary percutaneous coronary intervention. Am J Cardiol. 2010;106:1225–33.
   PubMedGoogle Scholar
• Harjai KJ, Stone GW, Boura J, Grines L, Garcia E, Brodie B, Cox D, O’Neill WW, Grines C. Effects of prior beta-blocker therapy on clinical outcomes after primary coronary angioplasty for acute myocardial infarction. Am J Cardiol. 2003;91(6):655–60. doi:https://doi.org/10.1016/S0002-9149(02)03401-X.
   PubMed Web of Science ®Google Scholar